New combo therapy aims to knock back recurrent prostate cancer
NCT ID NCT03902951
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visible metastases. The main goal is to see how many achieve a very low PSA level (<0.05 ng/mL), which would indicate strong disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abiraterone acetate, apalutamide, leuprolide acetate, and stereotactic body radiation therapy (SBRT)
What this could lead to
If successful, this combination could offer a way to control recurrent prostate cancer that has spread to a few sites, potentially delaying the need for stronger treatments.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply to everyone. The drugs can cause side effects like fatigue, hot flashes, and liver issues, and the radiation may damage nearby healthy tissue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.